Issue: January 2015
October 21, 2014
1 min read
Save

Clinical trials accumulate data for novel anti-VEGF

Issue: January 2015
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — A new anti-VEGF indicated for use in wet age-related macular degeneration achieved clinically meaningful and durable vision improvement in several studies with reduced dosing, according to a speaker here.

Conbercept, a fusion protein produced in a manner similar to Elyea (aflibercept, Regeneron) is approved for use in China, and discussions are underway to bring this drug to the U.S. and other countries, Peter K. Kaiser, MD, told colleagues at the Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.

Peter Kaiser

Peter K. Kaiser

“This drug actually lasts slightly longer — about a week or so is the half-life in vitreous. There’s a longer activity time than in other fusion proteins,” Kaiser said.

Results of the HOPE, AURORA, BRIDGE and PHOENIX clinical trials conducted in China led to the approval of conbercept there.

“It appears to have a durable visual acuity and meaningful visual acuity result and hopefully will offer us something more outside the country of China,” Kaiser said.

Disclosure: Kaiser has relevant financial relationships with Alcon, Bayer, Genentech, Chengdu Kanghong Biotech, Novartis, Ohr Pharmaceuticals, Ophthotech and Regeneron.